Today: 9 April 2026
Opendoor stock today jumps 4% — what moved OPEN and what traders are watching next
3 January 2026
1 min read

Opendoor stock today jumps 4% — what moved OPEN and what traders are watching next

NEW YORK, January 3, 2026, 07:27 ET — Market closed.

Opendoor Technologies Inc shares rose 4.1% to $6.07 at Friday’s close, ending the first U.S. trading session of 2026 with a sharp move in a stock that has stayed sensitive to shifts in risk appetite. MarketWatch

The rally matters now because Opendoor sits at the intersection of housing demand and interest rates — two variables investors are re-pricing at the start of a new year. Higher rates tend to cool homebuying and refinancing activity, while lower rates can help transactions and demand.

The company also entered 2026 with key leadership changes taking effect, including the appointment of Christy Schwartz as chief financial officer on Jan. 1, according to a December announcement. “We looked everywhere,” CEO Kaz Nejatian said in that release. SEC

Trading in OPEN was active on Friday, with about 38.4 million shares changing hands and the stock trading between $5.86 and $6.15, according to market data.

Moves across housing-linked names were mixed. Offerpad Solutions Inc, another iBuyer, gained 10.8%, while Zillow Group Inc fell 3.4%.

Broader markets ended uneven as investors focused on the outlook for Federal Reserve policy. The yield on the benchmark 10-year U.S. Treasury note rose to 4.191% as markets looked ahead to the next round of employment data for signals on growth and rate expectations, Reuters reported. Reuters

Opendoor operates an “iBuyer” model — it buys homes directly, then resells them. That can speed up transactions for customers, but it also exposes the company to home-price swings and the cost of financing inventory.

A December SEC filing also flagged share-price hurdles tied to performance restricted stock units, or PRSUs — stock awards that vest only if performance targets are met. Some targets referenced an average closing price of $6.24, with higher hurdles extending into the teens and beyond, the filing showed. SEC

Before the next session, traders will be watching whether Friday’s strength holds after a weekend break, especially with rate-sensitive sectors reacting quickly to changes in bond yields. Any fresh housing or macro headlines that shift rate expectations can show up fast in high-beta names like OPEN.

The next company milestone is earnings. Opendoor is expected to report results in late February, with an earnings calendar estimate pointing to Feb. 26. Nasdaq

When it reports, investors will be looking for signals on inventory risk, the pace of home purchases and resales, and how funding conditions are affecting margins and liquidity. Guidance on 2026 volumes and cost discipline will likely set the tone.

Stock Market Today

  • Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate
    April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow projections turning positive by 2026. However, actual cash flow remains negative at $501.5 million last year. Investors must weigh DCF optimism against market risks and sector volatility. Ultragenyx scores 4 out of 6 in valuation, indicating some appeal but highlighting areas needing scrutiny.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 09.04.2026

9 April 2026
LIVEMarkets rolling coverageStarted: April 9, 2026, 12:00 AM EDTUpdated: April 9, 2026, 2:11 AM EDT Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow
Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Apple stock today: AAPL starts 2026 on a softer note as valuation talk returns, Vision Pro in focus
Previous Story

Apple stock today: AAPL starts 2026 on a softer note as valuation talk returns, Vision Pro in focus

NYSE owner ICE stock slips below $160 as 2026 trading begins; jobs data in focus
Next Story

NYSE owner ICE stock slips below $160 as 2026 trading begins; jobs data in focus

Go toTop